eli lilly glp 1 agonist is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating Lilly Launches Trulicity in the
Description
In our study, GLP-1-RAs significantly reduced the (relative) number of MHD, with no patient from the GLP-1-RA group suffering from chronic headache at M6
Retatrutide, as a novel triple agonist with potentially superior efficacy, will almost certainly be priced in the same range or higher
But thats not the whole story
Lancet 381, 117124
Unverified Online Sellers: Sells to anyone for rapid weight loss
Neth J Med (1990) 37:116
